DURHAM, N.C., April 25, 2018 -- Tergus today announced key leadership changes to improve performance and accelerate growth.
A key component of this stage in Tergus’ expansion is the infusion of new talent and seasoned leadership into the business.
Michael Stenberg has been appointed Vice President, Business Development. In this role his early focus will be in the areas on identifying processes aimed at developing and onboarding new business opportunities that fit Tergus’ current business model as well as implementing growth opportunities. Mike joined Ei LLC in December 2009 (then Harmony Labs) and held positions of increasing responsibility until serving in his final capacity as VP of Business Development. He was a key member in creating, launching and promoting EnDev Laboratories along with its new skin biology capabilities. Prior to joining Ei LLC Mike worked at DPT Laboratories holding management positions in Project Management and Business Development.
William (BJ) Schaefer has also joined Tergus in the capacity of Senior Director, Technical Operations and Quality Control. BJ is tasked with reviewing and streamlining manufacturing operations and quality control. His ASQ-Certificate as a Six Sigma Black Belt will be highly relevant as we evaluate methods and improve our processes and outcomes. BJ has held roles in research, process improvement, technical transfer, quality and manufacturing and within both small and large organizations such as Multidata, Mallinckrodt, KV, Patheon, ConAgra, GSK, Virbac and Ei Solutionworks.
Charles Gray remains Site Head at EnDev Laboratories in Kannapolis. Charles joined EnDev in December 2010 to build a robust pharmaceutical development capability. He previously served as Director of Global CMC Regulatory Affairs and Executive Director, Global Product Development with Stiefel, a GSK Company. Prior to joining Stiefel, Charles spent 5 years with the U.S. Food and Drug Administration as a CMC (Chemistry, Manufacturing, and Controls) Reviewer for sterile products and as a Consumer Safety Officer in the FDA CDER Office of Compliance.
Jean-Philippe Therrien remains Vice President, Skin Biology having joined EnDev in November 2016. JP brings more than 20 years of experience in dermatological research and more than 9 years of experience in topical product development for both, prescription (Rx) and consumer healthcare/cosmetic (Cx) products, where his work has been extensively published in high-impact journals, scientific presentations, patent applications, and sale aids. JP is also a member of the Board of Directors of the Society of Investigative Dermatology.
“Exceptional leadership will advance Tergus’ strategic goals, branding, and customer support. This will lead to better customer experience and enhanced efficiency” said Vijendra Nalamothu, Ph.D., the Chief Executive Officer of Tergus Pharma, LLC. He added “ensuring we have the right organizational structure in place is critical to improving execution and increasing effectiveness. Consistent with the strategy articulated when EnDev Labs was acquired, this leadership team will strengthen Tergus’ capabilities and competitiveness as an industry leader in the dermatological space.”
Tergus Pharma is an end-to-end service provider for topical pharmaceutical research, drug development, testing and manufacturing company, has been an industry leader for several years with state-of-the-art facilities in Durham, North Carolina and Kannapolis, North Carolina.
Media Contacts: Clare Valcore + 1 (919) 549 9702 [email protected]


Tesla Weighs China Business Separation Amid SpaceX Merger Speculation
Arm Holdings Q1 Earnings Beat Estimates, Strong Q2 Outlook Fails to Lift ARM Stock
Sony Raises Full-Year Outlook After Q1 Profit Jumps 40% on Gaming and Chip Growth
Roblox Stock Drops 16% as Q3 Bookings Forecast Misses Expectations
Russia Charges Telegram Founder Pavel Durov With Facilitating Terrorism, Seeks International Arrest
WestJet Cancels 86 Flights as CUPE Strike Threat Disrupts Travel
Japan Earthquake Disrupts Auto and Chip Supply Chains
Toyota First-Half Global Sales and Production Decline on Weak China Demand, RAV4 Transition
Warner Bros. Discovery Shares Rise as Newsom Pushes Settlement in $110 Billion Merger Fight
Nike China Strategy to Lift Margins Despite $1 Billion Sales Hit, Bernstein Says
SpaceX Wins $1.6 Billion U.S. Space Force Launch Contracts for Falcon 9 Missions Through 2027
Amazon Q2 Earnings Beat Estimates as AWS AI Growth Surges, But Q3 Revenue Forecast Disappoints
Sony Eyes $1.3 Billion Tamron Acquisition as Lens Maker Reviews Offer
Robinhood Q2 Earnings Beat Estimates, But HOOD Stock Falls as Investors Question Profit Quality
Anthropic Reveals Claude AI Accessed Real Production Systems During Cybersecurity Tests
Starbucks Stock Jumps as Q3 Earnings Beat, Sales Growth Drives Higher 2026 Outlook
Same sparkle, different story: how lab-grown diamonds are transforming the market 



